HYHongbo Yang

Hongbo Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hongbo Yang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Automated Severity Grading of Pulmonary Hypertension Using Heart Sound Analysis

    by Lehan Zou, Feng Zhao, Hongbo Yang, Yan Chen, Weilian Wang

  • Open Access

    Inhibiting H2AX Can Ameliorate Myocardial Ischemia/Reperfusion Injury by Regulating P53/JNK Signaling Pathway

    by Ziyang Yu, Yirong Teng, Hongbo Yang, Yudi Wang, Xichen Li, Lei Feng, Wenbo Xu, Yinglu Hao, Yanping Li

    Myocardial ischemia‐reperfusion (I/R) injury is a significant area of focus in cardiovascular disease research. I/R injury can increase intracellular oxidative stress, leading to DNA damage. H2AX plays a crucial role in DNA repair. This study utilized mouse and cell models of myocardial I/R to investigate the impact of H2AX on cardiomyocytes during I/R. This study initially assessed the expression of H2AX in MI/R mice compared to a sham surgery group. Subsequently, cardiac function, infarct area, and mitochondrial damage were evaluated after inhibiting H2AX in MI/R mice and a negative control group. Furthermore, the study delved into the molecular mechanisms by analyzing the expression of H2AX, P53, p‐JNK, SHP2, p‐SHP2, p‐RAS, parkin, Drp1, Cyt‐C, Caspase‐3, and Caspase‐8 in cardiomyocytes following the addition of JNK or P53 agonists. The results from western blotting in vivo indicated significantly higher H2AX expression in the MI/R group compared to the sham group. Inhibiting H2AX improved cardiac function, reduced myocardial infarct area, and mitigated mitochondrial damage in the MI/R group. In vitro experiments demonstrated that inhibiting H2AX could attenuate mitochondrial damage and apoptosis in myocardial cells by modulating the P53 and JNK signaling pathways. These findings suggested that inhibiting H2AX may alleviate myocardial I/R injury through the regulation of the P53/JNK pathway, highlighting H2AX as a potential target for the treatment of myocardial ischemia/reperfusion injury.


  • Open Access

    Application of Artificial Intelligence-Based Auxiliary Diagnosis in Congenital Heart Disease Screening

    by Hongbo Yang, Jiahua Pan, Weilian Wang, Tao Guo, Tengyuan Ma

    To evaluate the application value of artificial intelligence-based auxiliary diagnosis for congenital heart disease. From May 2017 to December 2019, 1892 cases of congenital heart disease heart sounds were collected for learning- and memory-assisted diagnosis. The diagnosis rate and classification recognition were verified in 326 congenital heart disease cases. Auscultation and artificial intelligence-assisted diagnosis were used in 518 258 congenital heart disease screenings, and the detection accuracies of congenital heart disease and pulmonary hypertension were compared. Female sex and age > 14 years were predominant in atrial septal defect (P < .001) compared with ventricular septal defect/patent ductus arteriosus cases. Family history was more prominent in patent ductus arteriosus patients (P < .001). Compared with no pulmonary arterial hypertension, a male predominance was seen in cases of congenital heart disease–pulmonary arterial hypertension (P < .001), and age was significantly associated with pulmonary arterial hypertension (P = .008). A high prevalence of extracardiac anomalies was found in the pulmonary arterial hypertension group. A total of 326 patients were examined by artificial intelligence. The detection rate of atrial septal defect was 73.8%, which was different from that of auscultation (P = .008). The detection rate of ventricular septal defect was 78.8, and the detection rate of patent ductus arteriosus was 88.9%. A total of 518 258 people from 82 towns and 1220 schools were screened including 15 453 suspected and 3930 (7.58%) confirmed cases. The detection accuracy of artificial intelligence in ventricular septal defect (P = .007) and patent ductus arteriosus (P = .021) classification was higher than that of auscultation. For normal cases, the recurrent neural network had a high accuracy of 97.77% in congenital heart disease–pulmonary arterial hypertension diagnosis (P = .032). Artificial intelligence-based diagnosis is an effective assistance method for congenital heart disease screening.